Pliant Therapeutics Reports Narrowed Annual Loss, Advances Lead Oncology Program PLN-101095

summarizeSummary

Pliant Therapeutics reported a narrowed net loss for 2025 and is accelerating the development of its lead oncology candidate, PLN-101095, following positive Phase 1 data, while also confirming the discontinuation of its Bexotegrast program.

check_boxKey Events

• Narrowed Annual Net Loss

  The company reported a net loss of $149.3 million for the year ended December 31, 2025, a significant improvement from the $210.3 million net loss in 2024.

• Lead Oncology Program Advancement

  Following positive Phase 1 data for PLN-101095 in solid tumors, Pliant Therapeutics plans to accelerate its development with a Phase 1b indication expansion trial in 2026, with interim data expected in 2027. This follows recent news of positive Phase 1 data on March 11, 2026.

• Strategic Program Discontinuation and Restructuring

  Pliant discontinued the development of Bexotegrast in Idiopathic Pulmonary Fibrosis (IPF) and Primary Sclerosing Cholangitis (PSC) in March and June 2025, respectively. This strategic realignment included workforce reductions in May and December 2025, resulting in decreased R&D and G&A expenses.

• Liquidity and Capital Resources

  As of December 31, 2025, the company held $192.4 million in cash, cash equivalents, restricted cash, and short-term investments, which it believes will fund operations for the next 12 months and beyond. An At-The-Market (ATM) program for up to $150.0 million remains available for future capital raises.

auto_awesomeAnalysis

Pliant Therapeutics' annual report highlights a strategic pivot and improved financial efficiency, with a significantly narrowed net loss in 2025. The company is accelerating its lead oncology program, PLN-101095, into a Phase 1b expansion trial following positive Phase 1 data, which is a critical development for a clinical-stage biotech. This positive clinical momentum is balanced against the discontinuation of the Bexotegrast program in IPF and PSC, which led to workforce restructuring and reduced R&D expenses. While the company maintains sufficient liquidity for the near term, its substantial accumulated deficit and the existence of an ATM program indicate a continued need for capital in the future.